(E)-butyl 3-(4-isopropylphenyl)acrylate | 1609667-10-8

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: (E)-butyl 3-(4-isopropylphenyl)acrylate
• 英文别名: butyl (E)-3-(4-isopropylphenyl)acrylate；butyl (E)-3-(4-propan-2-ylphenyl)prop-2-enoate
• CAS: 1609667-10-8
• 化学式: C₁₆H₂₂O₂
• 分子量: 246.349
• InChiKey: CLKORBXBOPUWBR-DHZHZOJOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  18
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  丙烯酸丁酯 、 4-溴异丙苯 在 N-甲基二环己基胺 、 palladium diacetate 、 3-(4,8-dimethyl-2-phosphabicyclo[3.3.1]nonan-2-yl)-N,N-dimethylpropan-1-amine 作用下， 以 N,N-二甲基乙酰胺 为溶剂， 反应 24.0h， 以73%的产率得到(E)-butyl 3-(4-isopropylphenyl)acrylate
  参考文献：
  名称：

  柠檬烯衍生的双环膦促进钯催化的 Heck 反应

  摘要：

  摘要 衍生自 (R)-(+)-柠檬烯的叔双环膦为 Heck 交叉偶联反应提供了高效的钯催化剂。总体而言，获得了所需芳基烯烃产物的高产率，用于空间和电子多样化底物的交叉偶联。在商业酮的合成中进一步证明了催化剂的效率，例如覆盆子酮及其衍生物。

  DOI：

  10.1080/00397911.2022.2093646

文献信息

• Rhodium(II)-Catalyzed Nondirected Oxidative Alkenylation of Arenes: Arene Loading at One Equivalent
  作者：Harit U. Vora、Anthony P. Silvestri、Casper J. Engelin、Jin-Quan Yu

  DOI：10.1002/anie.201310539

  日期：2014.3.3

  bimetallic RhII catalyst promoted the CH alkenylation of simple arenes at 1.0 equivalent without the use of a directing group. A phosphine ligand as well as cooperative reoxidation of RhII with Cu(TFA)2 and V2O5 proved essential in providing monoalkenylated products in good yields and selectivities, especially with di‐ and trisubstituted arenes.

  双金属的Rh II催化剂促进与c  H在1.0当量，而无需使用定向基团的简单的芳烃的烯基化。膦配体以及Rh II与Cu（TFA）2和V 2 O 5的协同再氧化被证明对于以高收率和选择性提供单烯基化产物至关重要，特别是对于二取代和三取代的芳烃。
• Analogs of fexaramine and methods of making and using
  申请人：Salk Institute for Biological Studies

  公开号：US10450277B2

  公开（公告）日：2019-10-22

  Novel compounds having a formula embodiments of a method of making the same, and of a composition comprising them are disclosed herein. Also disclosed are embodiments of a method of treating or preventing a metabolic disorder in a subject, comprising administering to a subject (e.g., via the gastrointestinal tract) a therapeutically effective amount of one or more of the disclosed compounds, thereby activating FXR receptors in the intestines, and treating or preventing a metabolic disorder in the subject. Additionally disclosed are embodiments of a method of treating or preventing inflammation in an intestinal region of a subject, comprising administering to the subject (e.g., via the gastrointestinal tract) a therapeutically effective amount of one or more of the disclosed compounds, thereby activating FXR receptors in the intestines, and thereby treating or preventing inflammation in the intestinal region of the subject.

  具有以下式子的新型化合物 本文公开了具有式的新型化合物、其制造方法的实施方案以及包含它们的组合物。还公开了一种治疗或预防受试者代谢紊乱的方法的实施方案，包括向受试者施用（例如通过胃肠道）治疗有效量的一种或多种已公开化合物，从而激活肠道中的FXR受体，治疗或预防受试者的代谢紊乱。此外，还公开了一种治疗或预防受试者肠道区域炎症的方法的实施方案，该方法包括向受试者施用（例如，经由胃肠道）治疗有效量的一种或多种所公开化合物，从而激活肠道中的FXR受体，进而治疗或预防受试者肠道区域的炎症。
• ANALOGS OF FEXARAMINE AND METHODS OF MAKING AND USING
  申请人：Salk Institute for Biological Studies

  公开号：US20190084939A1

  公开（公告）日：2019-03-21

  Novel compounds having a formula embodiments of a method of making the same, and of a composition comprising them are disclosed herein. Also disclosed are embodiments of a method of treating or preventing a metabolic disorder in a subject, comprising administering to a subject (e.g., via the gastrointestinal tract) a therapeutically effective amount of one or more of the disclosed compounds, thereby activating FXR receptors in the intestines, and treating or preventing a metabolic disorder in the subject. Additionally disclosed are embodiments of a method of treating or preventing inflammation in an intestinal region of a subject, comprising administering to the subject (e.g., via the gastrointestinal tract) a therapeutically effective amount of one or more of the disclosed compounds, thereby activating FXR receptors in the intestines, and thereby treating or preventing inflammation in the intestinal region of the subject.
• [EN] ANALOGS OF FEXARAMINE AND METHODS OF MAKING AND USING<br/>[FR] ANALOGUES DE LA FEXARAMINE ET LEUR PROCÉDÉS DE PRÉPARATION ET D'UTILISATION
  申请人：SALK INST FOR BIOLOGICAL STUDI

  公开号：WO2017078927A1

  公开（公告）日：2017-05-11

  Novel compounds having a formula (I), embodiments of a method of making the same, and of a composition comprising them are disclosed herein. Also disclosed are embodiments of a method of treating or preventing a metabolic disorder in a subject, comprising administering to a subject (e.g., via the gastrointestinal tract) a therapeutically effective amount of one or more of the disclosed compounds, thereby activating FXR receptors in the intestines, and treating or preventing a metabolic disorder in the subject. Additionally disclosed are embodiments of a method of treating or preventing inflammation in an intestinal region of a subject, comprising administering to the subject (e.g., via the gastrointestinal tract) a therapeutically effective amount of one or more of the disclosed compounds, thereby activating FXR receptors in the intestines, and thereby treating or preventing inflammation in the intestinal region of the subject.
• Palladium-catalyzed Heck reactions promoted by limonene-derived bicyclic phosphines
  作者：Boitumelo Setati、Paseka Thendo Moshapo、Cedric Wahl Holzapfel、Munaka Christopher Maumela

  DOI：10.1080/00397911.2022.2093646

  日期：2022.7.18

  Abstract Tertiary bicyclic phosphines derived from (R)-(+)-limonene provided efficient palladium catalysts for Heck cross-coupling reactions. Overall, high yields of the desired aryl alkenes products were obtained for cross-coupling of sterically and electronically diverse substrates. The efficiency of the catalysts was further demonstrated in the synthesis of commercial ketones, such as raspberry

  摘要 衍生自 (R)-(+)-柠檬烯的叔双环膦为 Heck 交叉偶联反应提供了高效的钯催化剂。总体而言，获得了所需芳基烯烃产物的高产率，用于空间和电子多样化底物的交叉偶联。在商业酮的合成中进一步证明了催化剂的效率，例如覆盆子酮及其衍生物。